Holen Sie sich die Stockscreener-App
69.69
0.85%
0.59
Handel nachbörslich:
69.99
0.30
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ZTS?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$69.10
Offen:
$69.12
24-Stunden-Volumen:
5.25M
Relative Volume:
0.96
Marktkapitalisierung:
$28.80B
Einnahmen:
$9.51B
Nettoeinkommen (Verlust:
$2.64B
KGV:
11.55
EPS:
6.0361
Netto-Cashflow:
$2.14B
1W Leistung:
-1.91%
1M Leistung:
-8.51%
6M Leistung:
-40.91%
1J Leistung:
-52.43%
1-Tages-Spanne:
$68.77
$70.10
1-Wochen-Bereich:
$68.77
$71.70
52-Wochen-Spanne:
$68.77
$148.79
Zoetis Inc Stock (ZTS) Company Profile
Firmenname
Zoetis Inc
Sektor
Telefon
973-822-7000
Adresse
10 SYLVAN WAY, PARSIPPANY, NJ
Compare ZTS vs TAK, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Zoetis Inc Stock (ZTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Buy |
| 2026-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-07-17 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-18 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-12 | Bestätigt | Stifel | Buy |
| 2023-12-19 | Fortgesetzt | Jefferies | Buy |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-09-21 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-08-14 | Hochstufung | Edward Jones | Hold → Buy |
| 2020-08-12 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-05-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-09-09 | Eingeleitet | Goldman | Buy |
| 2019-07-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2019-05-03 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-04 | Hochstufung | Stifel | Hold → Buy |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-22 | Herabstufung | Stifel | Buy → Hold |
| 2018-08-03 | Bestätigt | Stifel | Buy |
| 2018-04-19 | Bestätigt | Citigroup | Buy |
| 2018-03-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-02-16 | Bestätigt | Stifel | Buy |
| 2018-01-04 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Zoetis Inc Aktie (ZTS) Neueste Nachrichten
Fund Update: 1,398,638 ZOETIS (ZTS) shares added to CONFLUENCE INVESTMENT MANAGEMENT LLC portfolio - Quiver Quantitative
Zoetis stock hits 52-week low at $69.48 - Investing.com
Zoetis (ZTS) Could Be 25% Undervalued As Investors Question Growth - Simply Wall Street
Join Class Action to Recover Losses from Zoetis Inc. (ZTS) – Contact Levi & Korsinsky Before July 27, 2026 - ACCESS Newswire
Zoetis shares drop 71% since 2021 but remain a buy with strong margins and pipeline potential. - Pluang
Zoetis: Priced For The Worst, Worth Buying (NYSE:ZTS) - Seeking Alpha
Zoetis Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - GlobeNewswire Inc.
Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatch
Zoetis (NYSE:ZTS) Looks Like a Decent Value Stock - ChartMill
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Zoetis Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Trading the Move, Not the Narrative: (ZTS) Edition - Stock Traders Daily
Zoetis sets Nov 5 webcast for Q3FY26 earnings review - scanx.trade
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results - Business Wire
The public can watch Zoetis review its third-quarter results live on Nov. 5. - Stock Titan
Zoetis Inc. stock outperforms competitors despite losses on the day - MarketWatch
Zoetis stock falls as TD Cowen cuts its target - AD HOC NEWS
Zoetis stock hits 52-week low at 70.97 USD - Investing.com
Zoetis Inc. (ZTS) Stock Analysis: Exploring A 34% Potential Upside For Investors - DirectorsTalk Interviews
Zoetis Director Mark Stetter Acquires 342 Phantom Stock Units Under Deferred Compensation Plan - Kalkine Media
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note - Eastern Progress
Zoetis Stock: The Worst May Be Priced In (NYSE:ZTS) - Seeking Alpha
Stifel reiterates Zoetis stock rating at Hold on share concerns - Investing.com
Why this money manager bought UnitedHealth, Palantir and sold Zoetis - The Globe and Mail
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales - TradingView
Zoetis: Companion Animal Weakness Keeps Me On The Sidelines (NYSE:ZTS) - Seeking Alpha
Zoetis: An Undervalued Compounder Hiding In Plain Sight (NYSE:ZTS) - Seeking Alpha
Zoetis Stock: New Competition Changes The Story, But Not Yet The Rating (NYSE:ZTS) - Seeking Alpha
Zoetis Introduces Blood Parasite Detection and Enhanced Cell Classification to Vetscan Imagyst | Vet Candy News - Vet Candy
Zoetis Inc. (ZTS) - DirectorsTalk Interviews
Zoetis (NYSE:ZTS): A Quality Dividend Stock for Dividend Investors - ChartMill
Michael Burry Sells FLUT To Pile Into LULU Under $100 — Plus A New Bet On ZTS - TradingView
Why Are Zoetis (NYSE:ZTS) Diagnostics in S&P 500 Focus? - Kalkine Media
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Yahoo Finance
Zoetis Shares Slide Following Earnings RevisionEarnings Deceleration Risk - vinanet.vn
Zoetis Stock (ZTS) Opinions on Michael Burry Portfolio Update - Moomoo
Zoetis Taps Former GE HealthCare CFO Jay Saccaro as CFO and COO - The Healthcare Technology Report.
Paws and profits: Zoetis appoints global diagnostics president, NVA names chief medical officer, and more updates - DVM360
Zoetis (ZTS) Shares Drop After Earnings Revision - Yahoo Finance
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030 - GlobeNewswire Inc.
Zoetis Inc. (ZTS) Investor Outlook: Unlocking a 26.63% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Is Zoetis Stock Underperforming the S&P 500? - Yahoo Finance
Zoetis Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - BioSpace
Zoetis (ZTS) awards 81K stock units to its CFO - Stock Titan
Zoetis (NYSE:ZTS) Offers Value and Quality in One Attractive Package - ChartMill
Is It Too Late to Buy Zoetis Inc (ZTS) After 3.1% Rally? GF Value Says Undervalued - GuruFocus
A Look at Zoetis Inc (ZTS) After 3.2% Decline -- GF Value $180.6 - GuruFocus
The Bull Case For Zoetis (ZTS) Could Change Following FDA Emergency Use Authorization For Simparica Trio - simplywall.st
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business? - Yahoo Finance
Finanzdaten der Zoetis Inc-Aktie (ZTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.19%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):